PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
238.00 - 242.07
140.53 - 242.25
26.77M / 38.44M (Avg.)
25.64 | 9.39
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
21.58%
Revenue growth above 1.5x META's 12.29%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
23.69%
Gross profit growth above 1.5x META's 12.33%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
7.65%
EBIT growth 50-75% of META's 10.27%. Martin Whitman would suspect suboptimal resource allocation.
7.65%
Operating income growth under 50% of META's 16.44%. Michael Burry would be concerned about deeper cost or sales issues.
-2.35%
Negative net income growth while META stands at 10.17%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
93.97%
EPS growth above 1.5x META's 10.47%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
93.33%
Diluted EPS growth above 1.5x META's 11.04%. David Dodd would see if there's a robust moat protecting these shareholder gains.
0.26%
Slight or no buybacks while META is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
-4.77%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
No Data
No Data available this quarter, please select a different quarter.
1.81%
OCF growth under 50% of META's 6.39%. Michael Burry might suspect questionable revenue recognition or rising costs.
16.48%
Positive FCF growth while META is negative. John Neff would see a strong competitive edge in net cash generation.
773.35%
10Y revenue/share CAGR at 50-75% of META's 1223.16%. Martin Whitman would question if the firm’s offerings lag behind the competitor.
773.35%
5Y revenue/share CAGR above 1.5x META's 190.49%. David Dodd would look for consistent product or market expansions fueling outperformance.
773.35%
3Y revenue/share CAGR above 1.5x META's 77.04%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
607.66%
Below 50% of META's 2770.56%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
607.66%
5Y net income/share CAGR above 1.5x META's 304.58%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
607.66%
3Y net income/share CAGR above 1.5x META's 194.47%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
26.98%
AR growth well above META's 14.10%. Michael Burry fears inflated revenue or higher default risk in the near future.
No Data
No Data available this quarter, please select a different quarter.
8.68%
Asset growth above 1.5x META's 5.19%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
6.84%
1.25-1.5x META's 5.80%. Bruce Berkowitz sees if the firm's capital management strategies surpass the competitor's approach.
-100.00%
We’re deleveraging while META stands at 0.08%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
3.53%
R&D growth drastically higher vs. META's 6.52%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
34.16%
SG&A growth well above META's 12.01%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.